Defining the Biology of Upper Tract Urothelial Carcinoma and Therapy Implications 

At the Society of Urologic Oncology Annual Meeting, Bishoy Faltas, MD, Weill Cornell Medicine, and Christopher Wallis, MD, PhD, FRCSC, University of Toronto, delve into the genomics of upper tract urothelial carcinoma. Together, they break down the ongoing work to uncover the evolution of upper tract disease, the potential of FGFR inhibition in the adjuvant as well as neoadjuvant setting, and whether genetic testing should be performed routinely on biopsy specimens.